Alzheimer and Dementia

Welcome Message

We are delighted to welcome researchers, neurologists, neuroscientists, psychiatrists, geriatricians, psychologists, academicians, healthcare professionals, caregivers, and industry experts to the 6th International Conference on Alzheimer and Dementia, taking place on June 14–15, 2027, in Barcelona, Spain. The conference will provide an international platform to share research, exchange clinical knowledge, explore emerging technologies, and build scientific collaborations in Alzheimer’s disease and dementia. Key areas will include early detection, biomarkers, neuroimaging, genetics, cognitive health, disease-modifying therapies, precision medicine, artificial intelligence, digital health, rehabilitation, and compassionate dementia care. With the theme, “Advancing Brain Health Through Innovation and Compassionate Care,” the conference emphasizes combining scientific innovation with personalized care to promote earlier diagnosis, better treatment, improved quality of life, and stronger support for individuals and families affected by dementia.

About the Conference

Abstract Submission Guidelines – ALZHEIMER AND DEMENTIA 2027

Submit abstracts through the official Abstract Submission portal associated with the conference. Abstracts should be written in English (250–300 words) and accompanied by a 100–120-word presenter biography. Abstract submissions are welcome in Alzheimer’s and dementia-related fields, including Alzheimer’s disease, dementia, neurodegeneration, biomarkers, early diagnosis, neuroimaging, genetics, cognitive neuroscience, mild cognitive impairment, disease-modifying therapies, psychopharmacology, neuropsychology, cognitive rehabilitation, dementia care, caregiver support, artificial intelligence, digital health, precision medicine, healthy aging, vascular dementia, Lewy body dementia, frontotemporal dementia, clinical trials, and other related disciplines.

Presenting authors should provide:

• Full Name
• Institutional Affiliation
• Country
• Phone Number
• Email Address
• Photograph

Co-authors should provide their full names and institutional affiliations. All submissions should undergo scientific review by the conference review committee. Accepted presenters must complete conference registration and pay the applicable registration fee. Please ensure all submitted.

Sessions and Tracks

Track 1: Alzheimers Pathogenesis Disease Mechanisms

Alzheimer’s disease is a progressive neurodegenerative condition involving complex changes in brain structure and function. Research continues to examine amyloid-beta, tau pathology, neuroinflammation, synaptic dysfunction, and neuronal loss. Understanding disease mechanisms is important for developing earlier diagnostic and therapeutic strategies.Genetic and environmental factors may influence susceptibility and disease progression.  Advances in molecular neuroscience are providing new insights into disease development. Research is increasingly focusing on biological changes that occur before significant cognitive symptoms. Improved understanding of disease pathways may support the development of targeted interventions.Continued multidisciplinary research is essential for translating laboratory discoveries into clinical applications.

• Amyloid and tau pathology
• Neuroinflammation and neurodegeneration
• Genetic and molecular mechanisms

Track 2: Early Detection and Diagnosis

Early detection is becoming increasingly important in Alzheimer’s disease and dementia management. Modern diagnostic approaches combine clinical assessment with imaging, biomarkers, cognitive testing, and genetic information. Earlier identification may allow patients and families to plan care and consider appropriate interventions. Research is developing tools capable of identifying biological changes before advanced cognitive decline. Blood-based biomarkers are receiving increasing attention because of their potential accessibility and scalability. Digital cognitive assessments may provide additional information for monitoring changes over time. Artificial intelligence may improve the interpretation of complex diagnostic datasets. The future of diagnosis is moving toward earlier, more accurate, and biologically informed assessment.

• Early-stage Alzheimer’s detection
• Blood and cerebrospinal-fluid biomarkers
• Digital and AI-assisted diagnosis

Track 3: Neuroimaging and Brain Biomarkers

Neuroimaging provides important information about structural and functional changes associated with neurodegenerative disease. MRI and PET techniques are widely used in research and specialized clinical assessment. Advanced imaging can contribute to understanding amyloid deposition, tau pathology, brain atrophy, and metabolic changes. Researchers are developing multimodal approaches that combine imaging with fluid biomarkers. Artificial intelligence can assist with image analysis and identification of subtle neurological patterns. Improvements in imaging may support earlier disease characterization and treatment monitoring. Standardization of imaging protocols remains important for clinical and research applications. Future developments may provide increasingly precise biological profiles for individual patients.

• MRI and PET imaging
• Amyloid and tau imaging
• AI-based neuroimaging analysis

Track 4: Disease-Modifying Therapies

Disease-modifying treatments are changing the therapeutic landscape of Alzheimer’s disease. Research is increasingly focused on therapies designed to influence underlying disease biology rather than only symptoms. Anti-amyloid approaches have demonstrated the potential for modifying disease progression in selected patient populations. Additional research is investigating tau-targeted and neuroprotective approaches. Treatment selection requires careful consideration of disease stage, biomarkers, safety, and patient characteristics. Monitoring treatment response and potential adverse effects remains essential. Future therapies may target multiple biological pathways simultaneously. Continued clinical research is necessary to improve effectiveness, safety, accessibility, and long-term outcomes.

• Anti-amyloid therapies
• Tau-targeted treatments
• Emerging disease-modifying approaches

Track 5: Dementia and Neurodegenerative Disorders

Dementia encompasses a range of disorders that cause progressive impairment in cognition and daily functioning. Alzheimer’s disease is the most common cause, while vascular, Lewy body, frontotemporal, and mixed dementias are also important. Accurate differentiation can support appropriate management and treatment planning. Research continues to investigate overlapping pathological processes among neurodegenerative conditions. Clinical assessment often requires neurological, cognitive, psychiatric, and functional evaluation. Biomarkers may increasingly help distinguish different disease processes. Personalized management can address cognitive, behavioral, medical, and social needs. Improved disease classification may accelerate the development of targeted therapies.

• Alzheimer’s and vascular dementia
• Lewy body and frontotemporal dementia
• Mixed and atypical dementias

Track 6: Cognitive Decline and Mild Cognitive Impairment

Mild cognitive impairment may represent an intermediate stage between normal aging and dementia for some individuals. Early assessment can help identify individuals who may be at increased risk of future cognitive decline. Cognitive testing evaluates memory, attention, language, executive function, and other domains. Biomarkers and imaging can provide additional information regarding underlying pathology. Lifestyle interventions and management of vascular risk factors may contribute to brain health. Cognitive training and rehabilitation are being investigated as supportive approaches. Longitudinal monitoring can help clinicians identify changes in cognitive functioning. Research continues to improve risk prediction and individualized management strategies.

• Mild cognitive impairment
• Cognitive assessment
• Cognitive training and prevention

Track 7: Genetics and Precision Medicine

Genetic research has improved understanding of inherited and susceptibility factors associated with Alzheimer’s disease. Genes such as APOE are important in research on disease risk and biological mechanisms. Genomic technologies are enabling researchers to identify additional genetic pathways. Precision medicine aims to use biological information to guide prevention, diagnosis, and treatment decisions. Pharmacogenomics may help researchers understand differences in treatment response. Genetic counselling and responsible communication are important when discussing individual risk. Large-scale genomic studies may identify new therapeutic targets. Future approaches are expected to integrate genetics with biomarkers, imaging, and clinical information.

• APOE and genetic risk
• Genomic research
• Precision and personalized medicine

Track 8: Neuropsychology and Cognitive Rehabilitation

Neuropsychology contributes to the assessment of cognitive, behavioral, and emotional changes associated with dementia. Detailed cognitive evaluation can help identify strengths, limitations, and patterns of impairment. Cognitive rehabilitation aims to support independence and everyday functioning. Memory strategies and compensatory techniques may help individuals manage specific difficulties. Interventions can be adapted according to disease stage and individual needs. Family members and caregivers can participate in rehabilitation planning. Digital cognitive tools are increasingly being explored for assessment and intervention.
Research continues to evaluate effective approaches for maintaining function and quality of life.

• Neuropsychological assessment
• Cognitive rehabilitation
• Memory and compensatory strategies

Track 9: Behavioral and Psychological Symptoms of Dementia

Behavioral and psychological symptoms can significantly affect individuals living with dementia and their caregivers. Symptoms may include agitation, anxiety, depression, sleep disturbances, hallucinations, and behavioral changes. Assessment should consider medical, environmental, psychological, and communication-related factors. Non-pharmacological approaches are often important components of comprehensive management. Personalized interventions can address individual triggers and preferences. Caregiver education may improve communication and reduce distress. Medication may be considered in selected situations when clinically appropriate. Research continues to identify safer and more effective strategies for behavioral symptom management.

• Agitation and behavioral changes
• Depression, anxiety and psychosis
• Non-pharmacological interventions

Track 10: Dementia Care and Caregiver Support

Dementia affects not only individuals but also families, caregivers, and communities. Comprehensive care should address medical, cognitive, psychological, functional, and social needs. Caregiver education can improve understanding of disease progression and daily challenges. Respite services and community support can help reduce caregiver burden. Person-centered care emphasizes dignity, autonomy, preferences, and meaningful activities. Technology may support communication, monitoring, and access to care. Long-term care planning is important as disease progression affects independence. Research increasingly emphasizes integrated approaches that improve outcomes for both patients and caregivers.

• Person-centered dementia care
• Caregiver wellbeing
• Community and home-based support

Track 11: Artificial Intelligence and Digital Dementia Care

Artificial intelligence is creating new possibilities for Alzheimer’s research, diagnosis, monitoring, and care. Machine-learning models can analyze clinical, imaging, genetic, and behavioral information. Digital tools may assist with cognitive assessment and longitudinal monitoring. Remote technologies can help extend support beyond traditional healthcare settings. AI may contribute to identifying subtle patterns associated with early disease. Digital platforms can also support caregivers and improve communication with healthcare teams. Privacy, transparency, bias, validation, and clinical oversight remain essential considerations. Responsible technology integration could improve accessibility and personalization of dementia care.

• AI-assisted diagnosis
• Digital cognitive monitoring
• Technology-enabled dementia care

Track 12: Prevention, Brain Health and Healthy Aging

Prevention and brain-health strategies are becoming increasingly important as populations age. Research suggests that multiple modifiable health and lifestyle factors may influence cognitive health. Management of cardiovascular risk factors can form part of comprehensive brain-health strategies. Physical activity, healthy nutrition, adequate sleep, and social engagement are important areas of investigation. Cognitive stimulation and lifelong learning may support healthy brain aging. Public-health initiatives can improve awareness of dementia risk factors. Early identification of modifiable risks may create opportunities for intervention. Future prevention strategies are likely to combine medical, behavioral, and social approaches.

• Modifiable dementia risk factors
• Lifestyle and brain health
• Healthy cognitive aging

Track 13: Vascular Dementia, Cerebrovascular Contributions

Vascular disease can contribute significantly to cognitive decline and dementia. Stroke, small-vessel disease, hypertension, diabetes, and other vascular factors may affect brain function. Neuroimaging can help identify vascular changes associated with cognitive impairment. Prevention focuses on managing cardiovascular and cerebrovascular risk factors. Research increasingly recognizes interactions between vascular and neurodegenerative pathology. Early risk management may help reduce the burden of cognitive impairment. Multidisciplinary care can address neurological, cardiovascular, cognitive, and functional needs. Improving vascular health may therefore represent an important component of dementia prevention.

• Cerebral small-vessel disease
• Vascular risk management
• Stroke and cognitive impairment

Track 14: Frontotemporal Dementia and Lewy Body Dementia

Frontotemporal dementia and Lewy body dementia are important neurodegenerative disorders with distinct clinical characteristics. Front temporal dementia can prominently affect behaviour, personality, language, and executive functioning. Lewy body dementia may involve cognitive fluctuations, visual hallucinations, Parkinsonism, and sleep-related symptoms. Accurate diagnosis can be challenging because symptoms may overlap with other neurological conditions. Biomarkers and advanced imaging may improve diagnostic confidence. Treatment often requires careful management of cognitive, behavioral, neurological, and psychiatric symptoms. Family education is particularly important because disease manifestations can be complex. Research continues to develop better diagnostic tools and disease-specific therapies.

• Frontotemporal dementia
• Lewy body dementia
• Differential diagnosis and management

Track 15: Clinical Trials and Emerging Therapeutics

Clinical research is central to developing new treatments for Alzheimer’s disease and dementia. Trials are investigating disease-modifying therapies, symptomatic treatments, biomarkers, and combination approaches. Innovative trial designs may improve the efficiency of drug development. Biomarker-based participant selection can help identify individuals most likely to benefit from specific interventions. Digital tools may support remote monitoring and collection of real-world data. Safety monitoring remains essential throughout clinical development. Collaboration between academic institutions, pharmaceutical companies, clinicians, and patient communities can accelerate research. The ultimate objective is to translate promising discoveries into effective and accessible treatments.

• Clinical trial innovation
• Emerging therapeutics
• Biomarker-guided research

Track 16: Palliative Care and Advanced Dementia

Advanced dementia can involve complex physical, psychological, social, and ethical challenges. Palliative approaches focus on comfort, dignity, symptom management, and quality of life. Care planning should reflect individual preferences and values wherever possible. Families often require support when making decisions about advanced disease. Pain, nutrition, communication difficulties, behavioral symptoms, and other complications may require multidisciplinary care. Advance care planning can help clarify future preferences and treatment goals. Supportive services can reduce distress for patients and caregivers. Research continues to promote compassionate, person-centered approaches throughout the disease trajectory.

• Comfort-focused dementia care
• Advance care planning
• Family and caregiver support

Track 17: Global Dementia Research and Public Health

Dementia represents an increasing global health challenge as populations age. Differences in healthcare resources can influence diagnosis, treatment, and access to support services. Public-health strategies can improve awareness, prevention, early recognition, and care pathways. Global research collaboration is essential for understanding diverse populations and risk factors. Low-resource settings may benefit from scalable diagnostic and care models. Digital technologies may help address geographic barriers to specialist services. Training healthcare workers can strengthen dementia recognition and management. International collaboration can support more equitable and sustainable dementia care.

• Global dementia burden
• Health-system responses
• Equitable dementia care

Track 18: Future Directions in Alzheimer’s and Dementia

The future of Alzheimer’s research is increasingly focused on early detection, biological characterization, and individualized intervention. Blood biomarkers, advanced imaging, genetics, and artificial intelligence may transform diagnostic pathways. Disease-modifying therapies are expanding the possibilities for intervention. Precision medicine may help match treatments to biological and clinical characteristics. Digital technologies can support monitoring, communication, rehabilitation, and caregiver assistance. Prevention research is also placing greater emphasis on modifiable risk factors and brain health. Ethical, economic, and accessibility considerations will remain important as new technologies and therapies emerge. Multidisciplinary collaboration will be essential for translating scientific progress into better outcomes for patients and families.

• Precision dementia care
• Emerging technologies and therapies
• Future models of dementia management.